Does protein aggregation drive postmitotic tissue degeneration?

Pharmacological evidence, from clinical trials where patients with systemic amyloid diseases are treated with disease-modifying therapies, supports the notion that protein aggregation drives tissue degeneration in these disorders. The protein aggregate structures driving tissue pathology and the commonalities in etiology between these diseases and Alzheimer's disease are under investigation.

Automated summary

Pharmacological evidence from clinical trials suggests that protein aggregation plays a key role in tissue degeneration in systemic amyloid diseases, with ongoing investigations focusing on the protein aggregate structures driving tissue pathology and the similarities in etiology between these diseases and Alzheimer's disease.